US EditionBeOne Medicines Showcases Leadership in B-cell Malignancies at ASH 2025
6 Articles
6 Articles
BeOne Medicines Showcases Leadership in B-cell Malignancies at ASH 2025
SAN CARLOS, Calif. -- BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, advances its vision to become the world’s leading oncology company with extensive new data from its differentiated hematology portfolio at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, Florida, December 6-9. Nearly 50 abstracts have been accepted, including six oral presentations, featuring the …
BeOne Medicines Showcases Leadership in B-cell Malignancies at ASH 2025
s at the ESMO 2025 Congress in Berlin, where it unveiled promising new data from two pivotal Phase 3 trials, RATIONAL...
BeOne Medicines: Pioneering Advances in Oncology with Promising Data from ASH 2025 and ESMO 2025' SAN CARLOS, California' BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235) is poised to maintain its status as a leader in innovative oncology solutions with significant advancements showcased at major medical conferences, including the American Society of Hematology (ASH) Annual Meeting in 2025 and the European Society of Medical Oncology…
Coverage Details
Bias Distribution
- 67% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
